IL17A and psoriasis: The TRPV1 and NaV1.8 neuroreceptors control the cutaneous immune response by interacting with dermal dendritic cells to inhibit the production of several key effector cytokines in psoriatic dermatitis and regulate the IL-23/IL-17 pathway.342 Neurons expressing TRPV1 can mediate itch signaling.343 However, intrathecal injection of capsaicin (10 μg) disrupts the central terminals of TRPV1-expressing neurons.344 Therefore, we hypothesize that TRPVs are considered novel targets for the treatment of psoriasis by suppressing itching to relieve psoriasis symptoms.